A bankruptcy judge Friday paved the way for Dendreon to auction its flagship, Provenge, to the highest bidder, a day after Valeant Pharmaceuticals set a $296 million floor price for the prostate cancer drug.
from WSJ.com: US Business http://ift.tt/1znDT7Y
via IFTTT
from WSJ.com: US Business http://ift.tt/1znDT7Y
via IFTTT
No comments:
Post a Comment